Neuronetics, Inc. (STIM), a commercial-stage medical technology company, on Tuesday announced the appointment of Steven Pfanstiel as Chief Financial Officer, effective July 15.
Pfanstiel will succeed Steve Furlong, who plans to retire on March 31, 2026. Furlong will stay on as Senior Advisor to the CEO until the end of March 2026 to support a smooth leadership transition.
Pfanstiel has two decades of experience in the healthcare industry and most recently served as Chief Financial Officer and Chief Operating Officer at publicly-traded Marinus Pharmaceuticals.
Looking ahead, the company reaffirmed its guidance for the second quarter and full year of 2025, citing the successful integration of Greenbrook operations and progress in key growth areas.
The company remains on track to achieve positive cash flow in the third quarter, a key step toward sustained profitability.
In the pre-market trading, Neuronetics is 1.81% higher at $3.93 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.